<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050500</url>
  </required_header>
  <id_info>
    <org_study_id>DAFLO-CH</org_study_id>
    <secondary_id>DAFLO</secondary_id>
    <nct_id>NCT05050500</nct_id>
  </id_info>
  <brief_title>The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction</brief_title>
  <official_title>The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin is one of the SGLT-2 inhibiters. Recent clinical trials have demonstrated that&#xD;
      SGLT-2 inhibitors are effective for treating heart failure. The DAPA-HF clinical trial has&#xD;
      demonstrated that the effects of empagliflozin and dapagliflozin improve renal outcomes and&#xD;
      reduce all-cause and cardiovascular death in patients with HFrEF[1]. However, its effect on&#xD;
      myocardial infarction, the most common disease leading to death in the population, has not&#xD;
      been evaluated sufficiently. A meta-analysis has demonstrated that compared with the control,&#xD;
      SGLT2 inhibitor is associated with a reduction in the incidence of major adverse&#xD;
      cardiovascular events (MACEs), myocardial infarction, cardiovascular mortality and all-cause&#xD;
      mortality[2]. It seems that dapagliflozin might be effective for patients with acute&#xD;
      myocardial infarction based on these studies. Thus, this study aims to evaluate the effect of&#xD;
      dapagliflozin on short-term prognosis in patients with acute myocardial infarction compared&#xD;
      to placebo.&#xD;
&#xD;
        1. Faiez Zannad, João Pedro Ferreira, Stuart J Pocock et el. SGLT2 inhibitors in patients&#xD;
           with heart failure with reduced ejection fraction: a meta-analysis of the&#xD;
           EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829.&#xD;
&#xD;
        2. Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang et el. Effects of SGLT2 inhibitors on&#xD;
           cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. Medicine&#xD;
           (Baltimore). 2019 Dec;98(49):e18245.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 8, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE events</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the occurence of myocardial infarction, stroke and death from cardiovascular causes in post-infarction patients during the follow-up time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular ejection fraction and left ventricular end-diastolic volume</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate baseline left ventricular ejection fraction (LVEF) and left ventricular end- diastolic volume(LVEDV) in post-MI patients and 6 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-infarction angina</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the post-infarction angina occurence in both groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of heart failure occurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Assess the rate of new-onset heart failure during the study follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Diabete Type 2</condition>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg every 24 hours for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo tablet every 24 hours for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg/Tab</intervention_name>
    <description>patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <other_name>Dapagliflozin Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Placebo Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with acute MI, either STEMI or NSTEMI, according to the fourth universal&#xD;
             definition of MI (Thygesen et al. 2019), disease onset within 7 days.&#xD;
&#xD;
          2. Previously diagnosed with type2 diabetes mellitus, newly diagnosed type2 diabetes&#xD;
             according to ADA criteria or glucose intolerance.&#xD;
&#xD;
          3. Capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form and the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with Type 1 Diabetes Mellitus.&#xD;
&#xD;
          2. Patients with renal dysfunction. (GFR&lt;90mmol/L).&#xD;
&#xD;
          3. Patients who have recently undergone immunosuppressive therapy.&#xD;
&#xD;
          4. Patients with a history of recurrent urinary tract infections.&#xD;
&#xD;
          5. Patients who are known to be allergic to SGLT-2 inhibitors.&#xD;
&#xD;
          6. Patients who are hemodynamically unstable.&#xD;
&#xD;
          7. Chronic symptomatic heart failure within the last year and known reduced ejection&#xD;
             fraction (LVEF≤40 %), documented before the current MI hospitalization.&#xD;
&#xD;
          8. Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the&#xD;
             trial.&#xD;
&#xD;
          9. Any other non cardiovascular diseases, such as active malignancy requiring treatment&#xD;
             at the time of screening or with a life expectancy of fewer than two years based on&#xD;
             the investigator´s clinical judgment.&#xD;
&#xD;
         10. Currently on treatment with a sodium-glucose co-transporter 2 inhibitor&#xD;
             (SGLT2-inhibitor).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weisheng Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Qingdao Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mengmei Li, MD</last_name>
    <phone>0086053284961672</phone>
    <email>sjogen@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mengmei Li</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>MACE events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

